Redburn Atlantic initiated coverage of Insulet with a Buy rating and $235 price target. Insulet has disrupted the insulin delivery market, and the company has sustained momentum as patch pumps continue to convert users to pump therapy, the analyst tells investors in a research note. The firm says Insulet’s “strong growth trajectory” should further enhance a sector-leading gross margin profile.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PODD:
Questions or Comments about the article? Write to editor@tipranks.com